Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Pipac With Abraxane

Research Leaders

8 sponsors active, led by Candiolo Cancer Institute - IRCCS

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03304210Phase 1Completed

PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer

SYF9e63bc7995084e4191f22afacb9a93a2Phase 2Unknown

PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

Showing all 2 trials

Research Network

Common Treatments

  • Pipac With Abraxane1
  • Ramucirumab1

Active Sponsors

  • Candiolo Cancer Institute - IRCCS1
  • Kom Op Tegen Kanker1
  • University Women's Hospital Tübingen1
  • University Hospital, Ghent1
  • Centre Hospitalier Universitaire Vaudois1

Top Investigators

Related Conditions

  • Breast Cancer Stage Iiic1
  • Ovarian Cancer Stage Iiic1
  • Pancreas Cancer Stage Iv1
  • Ovarian Cancer Stage Iv1
  • Peritoneal Carcinomatosis1

Activity Timeline